HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Clarins earnings

This article was originally published in The Rose Sheet

Executive Summary

Financial recovery expected in 2002 due to "resolution of logistical problems, a more ambitious marketing plan and the possibility of an upturn in consumption," French cosmetics firm says March 21. Operating profit in 2002 dropped 25.1% to $70.4 mil. (€1=$.88), and net profit plummeted 41.6% to $33.8 mil. Performance largely due to declines in American operations, which account for 22.6% of group sales, collapse of travel retail markets and transfer of manufacturing operations, Clarins says. Year-end sales, released earlier, increased 4.6% to approximately $755.2 mil. (1"The Rose Sheet" Feb. 11, 2002, p. 6)...

You may also be interested in...



Clarins Skin Care Fuels 3.2% Brand Sales Gain In 2001

The Clarins beauty brand generated $448.7 mil. (€1=$.86) worldwide in 2001, gaining 3.2% on an average currency basis largely on the strength of its core skin care business, the Parisian firm said

Roche Continues To Make The Case For Gantenerumab In Alzheimer’s Disease

The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.

Brinavess' US Review: EU Postmarket Data Unlikely To Save Troubled AFib Drug

Correvio's atrial fibrillation drug Brinavess will return to a US FDA advisory committee more than a decade after the agency first declined to approve the drug;  FDA still has a series of cardiovascular safety concerns related to the drug and is not convinced by data from the European experience.

UsernamePublicRestriction

Register

RS010159

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel